Introduction
============

Local translation at the synapse is an important mechanism for synaptic plasticity. Hundreds of mRNAs encoding signaling molecules, channels, neurotransmitter receptors, and components and regulators of the actin cytoskeleton, among other cellular functions, are selectively transported to distinct dendritic domains. There, their translation and stability is closely regulated upon stimulation by specific neurotransmitters or trophic factors by several RNA binding proteins (RBPs) and microRNAs. Deregulation of local translation compromises synapse formation and function, and provokes a plethora of neurological disorders. The human condition fragile X mental retardation syndrome is a dramatic example ([@bib89]; [@bib103], [@bib105]; [@bib79]; [@bib1]; [@bib88]; [@bib69]; [@bib31]; [@bib32]; [@bib107], [@bib108], [@bib109]; [@bib3]; [@bib5]; [@bib52]; [@bib91]; [@bib10]; [@bib30]; [@bib41]; [@bib84], [@bib85]; [@bib4]; [@bib43]; [@bib73]; [@bib80]; [@bib90]; [@bib98], [@bib99], [@bib100]; [@bib17]; [@bib42]; [@bib66]; [@bib26]; [@bib21]; [@bib37]; [@bib46]; [@bib62]; [@bib25]; [@bib28]; [@bib45]). Localized mRNAs are found in granules, collectively known as neuronal RNA granules, that contain specific RBPs including Staufen 1 and 2, Pumilio, fragile X mental retardation protein (FMRP), RNA granule protein 105 (RNG105), zipcode-binding protein 1 (ZBP1), survival of motor neuron (SMN), 4AIII, fused/translocated in sarcoma (FUS/TLS), and TAR DNA-binding protein 43 (TDP43), among others. Neuronal RNA granules serve as the functional units for transport and translational control ([@bib54]; [@bib55]; [@bib88]; [@bib50]; [@bib3]; [@bib41]; [@bib84]; [@bib105]; [@bib14]; [@bib80]; [@bib98]; [@bib42]; [@bib18]; [@bib101]; [@bib34]; [@bib62]; [@bib97]). In addition to neuronal RNA granules, the somatodendritic compartment contains processing bodies (PBs). PBs are ubiquitous mRNA-silencing foci, and they harbor untranslated mRNAs that can be released to allow translation. A plethora of PBs that differ subtly on composition are present in mammalian and insect neurons, and remarkably, neuronal PBs were recently shown to respond to synaptic stimulation ([@bib14]; [@bib22]; [@bib78]; [@bib110]; [@bib29]; [@bib65]; [@bib97]). Finally, stress granules (SGs), which are ubiquitous mRNA-silencing foci specific to the stress response, transiently form in neurons exposed to a variety of noxious stimuli. Several RBPs present in neuronal RNA granules are recruited to SGs, where they regulate mRNA translation, aggregation, and molecular motor recruitment ([@bib95], [@bib96]; [@bib84]; [@bib98]; [@bib27]; [@bib60]; [@bib16]; [@bib59]).

In this paper, we investigated the relevance of mammalian Smaug1/Samd4A, a posttranscriptional regulator that belongs to a novel family of RBPs ([@bib7]), in translational regulation at the synapse. Smaug was initially described in *Drosophila melanogaster*. In this organism, Smaug controls the stability and translation of hundreds of maternal mRNAs during early development ([@bib86]; [@bib24]; [@bib87]; [@bib67]; [@bib82], [@bib83]; [@bib94]; [@bib15]). *Drosophila* Smaug mediates mRNA silencing by multiple mechanisms. One of them involves the recruitment of Cup, which binds eukaryote initiation factor 4E, thus interrupting its interaction with eukaryote initiation factor 4G and blocking translation initiation ([@bib67]). More recently, fly Smaug was shown to block cap-dependent and independent translation by forming a highly stable repressed messenger RNP ([@bib48]). *Drosophila* Smaug is also able to trigger deadenylation by recruiting the CCR4--NOT complex and specific Piwi-interacting RNAs ([@bib106]; [@bib83]; [@bib76]). The yeast homologue Vts1 similarly triggers deadenylation of target mRNAs by recruiting the CCR4--NOT complex ([@bib75]). Two homologous genes, Smaug1/Samd4A and Smaug 2, are present in the mammalian genome. In a previous study, we reported that mammalian Smaug1 is present in the central nervous system and absent from nonneuronal cell lines ([@bib9]). Mammalian Smaug1 represses the translation of mRNAs carrying a specific motif termed Smaug recognition element (SRE), which mediates the binding of the *Drosophila* and yeast molecules to their targets ([@bib86]; [@bib24]; [@bib87]; [@bib23]; [@bib7], [@bib8]; [@bib44]; [@bib39]; [@bib82]; [@bib49]; [@bib68]; [@bib106]; [@bib94]; [@bib83]; [@bib38]; [@bib58]; [@bib74]). Here we found that Smaug1 forms granules in mature hippocampal neurons, which we have named S-foci, as they are apparently distinct from previously described neuronal RNA granules, as well as from PBs and SGs. S-foci are located at dendritic spines and behave as mRNA-silencing foci, being enhanced upon polysome breakdown, and disrupted upon polysome stabilization. We found that the Smaug1 RNA-binding domain is dispensable for S-foci formation, which indicates that Smaug1 aggregation is not the consequence of the binding to repressed mRNAs. Importantly, S-foci respond to synaptic stimulation, specifically to *N*-methyl-[d]{.smallcaps}-aspartic acid (NMDA) receptor (NMDAR) activation, which provokes the dissolution of the S-foci and the release of transcripts to allow their translation. We found that the messenger encoding the key molecule Ca^2+^/CaM-dependent protein kinase II (CaMKIIα) is apparently regulated by this novel mechanism. Unlike most RBP components of neuronal granules, which are also present in nonneural cells, Smaug1 is neuron-specific and its expression is triggered during synaptogenesis. Remarkably, we found that Smaug1 knockdown provokes the formation of smaller and more numerous synapses. Moreover, Smaug1-depleted neurons respond defectively to a repetitive depolarizing stimulus, as indicated by a reduced induction of activity-regulated cytoskeletal-associated protein (Arc/Arg3.1), an activity marker gene. Our results suggest that Smaug1 regulates localized translation upon synaptic stimulation, thus affecting synapse biogenesis and/or stability.

Results
=======

Smaug1 forms mRNA-silencing foci in cultured neurons
----------------------------------------------------

Having demonstrating the expression of Smaug1 in the central nervous system ([@bib9]), we analyzed the distribution of mammalian Smaug1 in mature neurons by immunofluorescence (IF). We found that Smaug1 forms granules ∼0.5 µm in diameter, which were present in the cell body and dendrites ([Fig. 1 A](#fig1){ref-type="fig"}). Smaug1 granules were distinct from those containing FMRP, an RBP involved in mRNA regulation ([Fig. 1 B](#fig1){ref-type="fig"}; [@bib10]; [@bib26]). As expected, primary fibroblasts and glial cells did not express Smaug1 (unpublished data; [@bib9]).

![**Mammalian Smaug1 is expressed in neurons and forms mRNA-silencing foci.** Cultured hippocampal neurons were stained for the indicated molecules. (A) Bars: (top) 5 µm; (bottom) 1 µm. (B) A magnification of an isolated dendrite is shown. Bar, 1 µm. (C) Hippocampal neurons were exposed to cycloheximide (CHX) or puromycin (PURO) during 3 h. The size and number of Smaug1 foci were measure in 100× confocal z-stack images and the area occupied by Smaug1 granules in 20 randomly selected dendrite fragments was calculated for each treatment. A moderate increase of Smaug1 granular signal was observed upon puromycin treatment, whereas exposure to cycloheximide provokes a moderate reduction of Smaug1 granular signal. Error bars indicate standard deviation.](JCB_201108159_Fig1){#fig1}

We have shown before that Smaug1 constructs transfected in nonneuronal cell lines form RNA granules that behave as silencing foci, as they are in dynamic equilibrium with translating polysomes ([@bib9]). We investigated whether neuronal Smaug1 foci behave similarly. We focused on dendritic granules, as the abundance of Smaug1 granules at the cell body precluded the analysis in this cell compartment. We found that a relatively long-exposure of cultured neurons to puromycin, a translation inhibitor that disrupts polysomes, enhanced the presence of Smaug1 granules, whereas cycloheximide, a drug that blocks elongation leading to ribosome stalling, provoked a moderate dissolution ([Fig. 1 C](#fig1){ref-type="fig"}). Shorter treatments had no effect (see [Fig. 6](#fig6){ref-type="fig"}). For comparison, the dynamics of neuronal PBs identified by decapping enzyme 1a (DCP1a) staining were similarly analyzed. We found that PBs dissolved faster than Smaug1 foci upon polysome stabilization (unpublished data). These observations are consistent with the behavior of PBs in nonneuronal cells (for reviews see [@bib40]; [@bib2]; [@bib11]; [@bib20]; [@bib56]; [@bib97]). Thus, dendritic Smaug1 granules behave as mRNA-silencing foci, and are apparently less dynamic than PBs. We named structures that contain Smaug1; exclude FMRP, SMN, and Staufen 1 ([Fig. 1](#fig1){ref-type="fig"}; unpublished data); and are distinct from PBs and SGs (see the following section) "S-foci."

Smaug1 foci are independent of PBs
----------------------------------

We investigated the relationship between S-foci and SGs and PBs. Neuronal S-foci appeared distinct from SGs formed upon exposure of neurons to an oxidative stress stimulus, but they were frequently found in the vicinity of SGs, thus resembling the behavior of PBs ([Fig. S1 A](http://www.jcb.org/cgi/content/full/jcb.201108159/DC1){#supp1}). In contrast, FMRP and Staufen were recruited to SGs, as described previously in neuronal and nonneuronal cells (Fig. S1 A; [@bib95], [@bib96]; [@bib27]; [@bib63]). We then analyzed the relationship between S-foci and PBs by visualizing DCP1a. We found that neuronal S-foci did not overlap with PBs identified by DCP1a. However, a significant proportion of the S-foci were detected in close contact with PBs (Fig. S1 B). Next, we investigated whether PBs are required for S-foci formation. We treated neurons with siRNAs against the PB components Hedls, Rck/p54, or 4ET, which are known to affect PB integrity in cell lines ([@bib35]; [@bib36]; [@bib96]). We found that the numbers of DCP1a foci were reduced upon depletion of any of the above molecules ([Fig. 2 A](#fig2){ref-type="fig"}), as reported recently in *Drosophila* neurons upon depletion of Rck/p54/Me31B ([@bib45]). We simultaneously analyzed the presence of the S-foci and found that their number or size were not affected by any of the treatments against PBs ([Fig. 2 A](#fig2){ref-type="fig"}). Conversely, Smaug1 depletion did not significantly affect the presence of PBs identified by DCP1a staining (Fig. S1 C). Collectively, these results indicate that PB integrity is not required for S-foci maintenance. However, the possibility that the S-foci were assembled before PB breakdown remained open. To investigate this, we used U2OS cells, which do not express Smaug1 ([@bib9]). As expected, transfected Smaug1-ECFP form cytoplasmic granules in U2OS ([Fig. 2, A--C](#fig2){ref-type="fig"}). Overexpression may provoke the formation of unfolded protein aggregates, and we considered this possibility. As described previously ([@bib9]), we found that Smaug1-ECFP foci are dynamic and behave as mRNA-silencing foci, thus discarding the possibility of abnormal protein aggregation. Transient overexpression of translational repressors may induce SGs ([@bib102]; [@bib97]), and therefore we investigated the relationship of Smaug1-ECFP foci with SGs. We found that eIF3η, an obligate component of SGs, is not recruited to the Smaug1-ECFP foci ([Fig. S2 A](http://www.jcb.org/cgi/content/full/jcb.201108159/DC1){#supp2}). However, as described previously ([@bib9]), the SG component TIA1/TIAR is present in a fraction of the larger Smaug1-ECFP foci (Fig. S2 A). This was restricted to the heterologous system, and TIA1/TIAR was never observed in neuronal S-foci*.* A significant proportion of Smaug1-ECFP foci were in close contact, or virtually coincident with PBs visualized by DCP1a, Hedls, or RCK/p54 ([Figs. 2 B](#fig2){ref-type="fig"} and S2 A). Then, we investigated the effect of PB breakdown. We first provoked PB disassembly by knockdown of Hedls, Rck/p54, or 4ET, as described previously ([@bib35]; [@bib36]; [@bib96]), and then transfected Smaug1-ECFP.

![**S-foci are independent of PBs.** (A) Neurons were treated with the indicated siRNA, and the presence of S-foci and PBs visualized by DCP1a staining was analyzed in 20 randomly selected dendrite fragments (400 µm total length) for each treatment. Normalized values from two independent experiments are plotted. Representative IF images for the indicated molecules upon the distinct treatments are shown. Bottom, depletion of PBs visualized by RCK or Hedls relative to normal levels. In all cases, knockdown of Hedls or RCK provokes PB disruption without affecting the presence of S-foci. Error bars indicate standard deviation. (B) U2OS cells were transfected with Smaug1-ECFP and immunostained for the indicated PB markers. Close vicinity between S-foci and PBs is frequent ([Fig. S2 A](http://www.jcb.org/cgi/content/full/jcb.201108159/DC1){#supp3}). The bottom row shows enlarged views of the boxed regions. (C) U2OS cells were treated with the indicated siRNAs, then transfected with the Smaug1-ECFP construct, and stained for DCP1a. Depletion of Hedls, Rck/p54, and 4ET was confirmed by Western blotting or RT-PCR (Fig. S2, B and C), and their effect on PB integrity was confirmed by IF (Fig. S2 D). Representative cells are depicted, and the percentage of the transfected cells with S-foci in each treatment is indicated. Similar results were observed in three independent experiments. The bottom row shows enlarged views of the boxed regions. (D) U2OS cells were transfected with the indicated constructs, and the proportion of the transfected cells with foci is indicated. One representative experiment out of five is shown. (E) U2OS cells expressing the indicated constructs were treated with cycloheximide (CHX), emetine (EME), puromycin (PURO), or hippuristanol (HIP) during 4 h, and stained for DCP1a. The proportion of cells with foci relative to that of untreated cells for each construct and the proportion of cells with PBs identified by DCP1a are plotted. S-foci and PBs disassembled upon polysome stabilization by cycloheximide or emetine, whereas ΔSAM foci were fully resistant. Normalized values from 50 cells from a representative experiment out of three are shown. Error bars in E represents the standard deviation from triplicate coverslips. Bars: (A) 1 µm; (B--D) 10 µm.](JCB_201108159_Fig2){#fig2}

The knockdown was confirmed by Western blot analysis of Hedls and Rck/p54, and by RT-PCR for 4ET (Fig. S2, B and C). As expected, a strong reduction in the proportion of cells with PBs was observed upon treatment with the above siRNAs (Fig. S2 D). Then, we analyzed the presence of Smaug1-ECFP foci. Strikingly, we found that between 40 to 47% of the transfected cells formed S-foci in all cases, which indicates that the PB components Hedls, Rck/p54, or 4E are not required for S-foci assembly in cell lines ([Fig. 2 C](#fig2){ref-type="fig"}).

It has been suggested that the assembly of mRNA-silencing foci is a consequence of silencing ([@bib33]; [@bib97]). We analyzed whether a Smaug1 truncate termed ΔSAM, which lacks the SAM domain that mediates RNA binding, was able to form foci ([Fig. 2 D](#fig2){ref-type="fig"}). As is the case for the full-length molecule, the ΔSAM foci were distinct from SGs (Fig. S2 A). We found that the SAM domain is dispensable for foci formation, and consistent with this observation, the isolated SAM domain did not form foci ([Fig. 2 D](#fig2){ref-type="fig"}). We speculate that the ΔSAM construct is not able to bind RNA, and thus we predict that ΔSAM foci will not respond to polysome stabilization, a distinctive feature of mRNA-silencing foci. As expected, we found that ΔSAM foci did not dissolve upon polysome stabilization by cycloheximide or emetine, whereas S-foci and PBs were significantly disassembled ([Fig. 2 E](#fig2){ref-type="fig"}), as described previously ([@bib9]). In spite of minor differences with neuronal S-foci, these observations in cell lines allowed us to conclude that S-foci formation is not the consequence of the binding to repressed mRNAs, and that neuron-specific factors are not required. In addition, S-foci formation is independent of PBs.

Synaptic Smaug1 silencing foci respond to NMDAR activation
----------------------------------------------------------

Regulated translation is known to occur at postsynaptic sites ([@bib89]; [@bib47]; [@bib3]; [@bib84]; [@bib80]). Thus, we analyzed the presence of Smaug1 silencing foci at the synapse surroundings. To identify synapses, we immunostained the presynaptic marker synapsin and the postsynaptic molecule PSD95 in cultured hippocampal neurons. We found that between 55 and 75% of synapses contain S-foci ([Fig. 3 A](#fig3){ref-type="fig"}). S-foci were detected in close contact with PSD95 clusters ([Fig. 3 A](#fig3){ref-type="fig"}), which suggests an association with the postsynaptic density, a scaffold structure that holds neurotransmitter receptors. In addition, we found that transfected Smaug1-ECFP similarly formed granules present in the somatodendritic compartment and at postsynapses ([Fig. 3 B](#fig3){ref-type="fig"}). For comparison, we simultaneously investigated the presence of FMRP granules and found that most synapses contained FMRP and/or Smaug1, and that their presence was not mutually exclusive ([Fig. 3 C](#fig3){ref-type="fig"}).

![**Smaug1 foci at the postsynapse.** (A and B) Magnifications of isolated dendritic spines showing endogenous Smaug1 (A) or transfected Smaug1-ECFP (B), and the indicated markers. Endogenous or transfected Smaug1 form granules located at the postsynapse. (C) Smaug1 and FMRP were simultaneously stained in cultured neurons, and their presence in the synapses was evaluated. (D) Adult hippocampus slices were stained with the indicated antibodies. (D, top left) Tubulin βIII. (D, bottom left) A magnification of the CA1 region, including cell bodies and dendrites is shown. PI, rabbit preimmune serum. (D, right) A representative magnification of the CA3 region showing four S-foci associated with a synapse. Enlarged views of the boxed regions are shown below. (E) Synaptoneurosomes (Sn) were isolated from adult hippocampus (Hipp) by sucrose gradient centrifugation, then separated in a soluble extract (Sol) that was enriched in presynaptic components and that excluded PSD95, and a postsynaptic density-enriched fraction (PSD). Smaug1 is detected in the synaptoneurosomal and PSD fractions, and is absent from the soluble presynaptic fraction. Bars: (A and B) 1 µm; (D, left) 5 µm; (D, right) 1 µm.](JCB_201108159_Fig3){#fig3}

We also analyzed the presence of Smaug1 granules in hippocampal slices ([Fig. 3 D](#fig3){ref-type="fig"}). Cell bodies and dendrites were strongly labeled by the anti-Smaug1 serum. In addition, Smaug1 granules frequently associated to synapsin clusters ([Fig. 3 D](#fig3){ref-type="fig"}). On average, 60% of synapsin patches contain one or two S-foci in their surroundings ([Fig. 3 D](#fig3){ref-type="fig"}, insets). Finally, we found that Smaug1 is present in hippocampal synaptosomes isolated by sucrose gradient centrifugation ([Fig. 3 E](#fig3){ref-type="fig"}). Moreover, Smaug1 copurified with PSD95 in postsynaptic densities isolated from synaptosomes by extraction with Triton X-100 at pH 8.0 ([@bib71]). Smaug1 is absent from the soluble fraction obtained by this procedure, which is enriched in presynaptic components and excludes postsynaptic molecules ([Fig. 3 E](#fig3){ref-type="fig"}; [@bib71]).

Translation at the postsynapse is finely regulated by synaptic stimulation, and we hypothesized that Smaug1-mediated repression is modulated by synaptic activity. We reasoned that if mRNA silencing by Smaug1 is released upon synaptic stimulation, the number and/or size of the S-foci will decrease. Conversely, the presence of S-foci is expected to increase if synaptic stimulation enhances repression by Smaug1. Then, we exposed neurons to a short depolarizing stimulus by increasing potassium concentration to 40 mM. We found that the number of synapses containing S-foci was significantly reduced upon stimulation ([Fig. 4 A](#fig4){ref-type="fig"}). The response was rapid; it was detected 1 min after depolarization, and 5 min after the stimulus the proportion of synapses with S-foci was reduced to 50% relative to basal levels. In addition, the size of the remaining S-foci was significantly reduced. A prolonged treatment of 30 min did not further increase the response ([Fig. 4 B](#fig4){ref-type="fig"}). S-foci dissolution was reversible, and 16 h later the presence of S-foci at synapses was fully recovered (unpublished data). Remarkably, the effect was observed in the S-foci associated with the synapses, identified by PSD95 or synapsin staining, whereas the S-foci located in the dendritic shaft were not significantly altered, which suggests that the dissolution of the S-foci involves a local response ([Fig. 4, B and C](#fig4){ref-type="fig"}).

![**S-foci located at postsynaptic sites respond to depolarization.** Hippocampal neurons were exposed to KCl as indicated in Materials and methods during the indicated time periods, and stained for the indicated proteins. (A) Representative dendrite fragments from control or depolarized neurons are shown. Synaptic Smaug1 signal is reduced in depolarized neurons. Bar, 1 µm. (B) The presence of S-foci in ∼600 synapses from 40 random-selected dendritic fragments, and the S-foci size from 100 random selected S-foci was evaluated at the indicated time points. Normalized values and standard deviation from duplicates are shown (error bars). (C) The number of S-foci in dendrite shafts after a 10-min KCl pulse was evaluated in triplicate experiments. The number of synapses remained constant through the analyzed time points (not depicted).](JCB_201108159_Fig4){#fig4}

We then investigated which synaptic receptors mediate S-foci dissolution. Most stimulatory hippocampal synapses respond to glutamate, whereas inhibitory synapses in these cells respond to γ-amino butyric acid (GABA). Next, we applied a short depolarizing stimulus in the presence of kynurenic acid, a blocker of the ionotropic glutamate receptors that respond to α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) or to NMDA. The effect of picrotoxin, a GABA-A receptor inhibitor, was also analyzed. We found that glutamate receptor blockage completely abrogated the dissolution of S-foci triggered by depolarization, whereas GABA-A receptor inhibition did not affect the response ([Fig. 5 A](#fig5){ref-type="fig"}).

![**S-foci respond to NMDAR activation.** (A--C) Hippocampal neurons were exposed to KCl during 10 min in the presence or absence of the indicated drugs, and the number of synapses with associated Smaug1 (A and B) or FMRP granules (C) was evaluated. KYNA, kynurenic acid; PICRO, picrotoxin. (D) Neurons were pulsed with NMDA as indicated in Materials and methods and allowed to recover, and the presence of S-foci at the synapses was analyzed. S-foci size normalized to control values at each time point is indicated. Similar results were observed in three independent experiments including different time points. (D, bottom) Representative IF images corresponding to the experiments depicted. Bar, 1 µm. (E and F) Neurons were exposed to KCl or NMDA in the presence of the indicated drugs, and the presence of S-foci associated to synapses was evaluated as in [Fig. 4 B](#fig4){ref-type="fig"}. E-AM, EGTA-AM; W, wortmannin; KN, KN93; LY, LY294002. Approximately 100 dendritic fragments from 20 neurons were analyzed for each data point. Error bars indicate standard deviation from triplicate coverslips in a representative experiment.](JCB_201108159_Fig5){#fig5}

![**S-foci dissolution upon synaptic stimulation requires polysome assembly.** (A--C) Hippocampal neurons were exposed to KCl or NMDA as indicated in Materials and methods, in the presence or absence of the indicated translation inhibitors. CHX, cycloheximide; PURO, puromycin; Hip, hippuristanol. (A and B) The proportion of synapses containing S-foci relative to basal levels from three independent experiments is plotted, and IF images of representative dendritic fragments for the indicated treatments are depicted. Bars, 1 µm. (C) TTX-silenced hippocampal cells were stimulated with NMDA in the presence or absence of cycloheximide or emetine (EME), which stall polysomes, and allowed to recover during 60 min, in the presence or absence of puromycin, which disrupts polysomes. S-foci were analyzed as in [Figs. 4](#fig4){ref-type="fig"} and [5](#fig5){ref-type="fig"}. The continuous inhibition of protein synthesis does not affect S-foci reassembly. Similar results were obtained in a duplicate experiment. Approximately 50 dendritic fragments (total length, 750 µm) from 20 neurons were analyzed for each data point. Error bars indicate standard deviation.](JCB_201108159_Fig6){#fig6}

Next, we investigated which glutamate receptor is involved. We used the NMDA antagonist 2-amino-5-phosphonopentanoate (APV) and the AMPA antagonist 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX). We found that NMDAR inhibition completely abrogated the response to depolarization, whereas AMPA receptor (AMPAR) inhibition had no effect on the dissolution of the S-foci triggered by KCl-mediated depolarization ([Fig. 5 B](#fig5){ref-type="fig"}). For comparison, we simultaneously analyzed the response of the FMRP granules. We found that FMRP granules responded to AMPAR activity, in agreement with a previous study ([@bib3]). In addition, we found that in contrast to the S-foci, FMRP granules were not affected by NMDAR activity ([Fig. 5 C](#fig5){ref-type="fig"}).

To further assess the role of NMDAR in S-foci dynamics, we exposed hippocampal neurons to a short pulse of NMDA. Before stimulation, hippocampal cells were treated with tetrodotoxin (TTX), which blocks the opening of the voltage-gated Na^+^ channel, thus leading to a depressed state. This treatment did not affect the S-foci significantly. TTX-treated neurons were stimulated over 5 min with 30 µM NMDA and allowed to recover. The number and size of the S-foci at synapses were measured at several time points after the stimulus. In agreement with the above results, we found that the S-foci dissolved upon NMDAR activation. The effect was immediate and reversible. 5 min after NMDA exposure, the number of synapses containing S-foci was reduced to \<50% relative to basal levels ([Fig. 5 D](#fig5){ref-type="fig"}), and the remaining foci were significantly smaller (0.52 µm^2^ in resting conditions vs. 0.37 µm^2^ immediately after the NMDA pulse). The effect lasted for 60 min after release of the stimulus, and cells started to recover within 6 h afterward ([Fig. 5 D](#fig5){ref-type="fig"}).

Next, we investigated whether calcium influx is involved in the response. We treated the neurons with the intracellular calcium chelator EGTA-AM shortly before and also during the depolarization stimulus. We found that intracellular Ca depletion abrogates S-foci dissolution, which indicates that calcium influx mediates the response ([Fig. 5 E](#fig5){ref-type="fig"}). Phosphoinositide 3-kinase (PI3K) and CaMKII are relevant kinases that are locally stimulated by calcium influx upon NMDA activation. To investigate the participation of these signaling pathways, we used pharmacological inhibitors: wortmannin or LY294002 against PI3K, and KN-93 against CaMKII. We found that PI3K inhibition blocked S-foci dissolution triggered either by KCl-mediated depolarization ([Fig. 5 E](#fig5){ref-type="fig"}) or by NMDAR activation ([Fig. 5 F](#fig5){ref-type="fig"}). Inactivation of CaMKII had no effect ([Fig. 5 F](#fig5){ref-type="fig"}). Whether Smaug1 is directly affected by PI3K remains to be investigated.

Smaug foci disassembly upon synaptic stimulation requires polysome assembly
---------------------------------------------------------------------------

We speculated that S-foci dissolution upon synaptic stimulation is linked to mRNA release and translation activation. Thus, we analyzed the effect of translational blockers that enhance or impair polysome stability. We found that cycloheximide or emetine, which provoke polysome stalling, did not affect the dissolution of the S-foci triggered by either KCl or NMDA ([Fig. 6, A and B](#fig6){ref-type="fig"}; and not depicted). In all cases, the number of synapses containing S-foci and the foci size were significantly reduced. In striking contrast, puromycin or hippuristanol, which impair polysome assembly, completely abrogated the response triggered by depolarization or by direct NMDAR activation ([Fig. 6, A and B](#fig6){ref-type="fig"}).

These results are compatible with the notion that S-foci dissolution upon NMDAR activation allows the release of silenced mRNAs and their recruitment to polysomes. When polysome assembly is impaired, mRNAs would return to the S-foci, counteracting the dissolution triggered by synaptic stimulation.

We wondered whether S-foci plasticity involves Smaug1 degradation during dissolution and de novo synthesis to allow reassembly. Against this possibility, we found that S-foci dissolution upon depolarization was not affected by the presence of the proteasome inhibitor MG132 (unpublished data). In addition, we followed S-foci dissolution and reassembly in the absence of protein synthesis, and found that the synthesis of new Smaug1 molecules is not required during aggregation ([Fig. 6 C](#fig6){ref-type="fig"}). As in [Fig. 6 (A and B)](#fig6){ref-type="fig"}, polysome-stabilizing drugs did not impair S-foci dissolution by NMDAR stimulation, and as expected ([Fig. 5 D](#fig5){ref-type="fig"}), S-foci remained disassembled for up to 1 h afterward ([Fig. 6 C](#fig6){ref-type="fig"}). S-foci recovery was enhanced in the presence of the translational inhibitor puromycin, which suggests that Smaug1 molecules cycle between aggregated and disaggregated states to regulate the availability of specific transcripts.

NMDA induces the dissociation of Smaug1 from CaMKIIα mRNA granules
------------------------------------------------------------------

CaMKIIα mRNA is known to be locally translated upon NMDA stimulation ([@bib47]; [@bib12]), and thus we sought to investigate whether the S-foci are involved in the regulation of this messenger. First, we analyzed whether Smaug1 and CaMKIIα mRNA colocalize. We performed FISH analysis and found that, as reported before, this transcript is present in granules in the soma and dendrites. Simultaneous staining of Smaug1 revealed that a significant proportion of CaMKIIα mRNA granules are associated with S-foci ([Fig. 7 A](#fig7){ref-type="fig"}). Both in the dendritic shaft and at the synapse surroundings, 45% of CaMKIIα mRNA granules associated with S-foci at a distance \<150 nm (averaged from three independent stainings), which is compatible with a intermolecular interaction, as described for other RBPs and their target mRNAs ([@bib42]).

![**CaMKIIα mRNA associates to S-foci in an activity-dependent manner.** (A) CaMKIIα mRNA and Smaug1 were simultaneously detected by FISH and IF, respectively. Between 40 and 60% of CaMKIIα mRNA granules colocalize or are in close contact with S-foci. A representative dendrite is shown. (B) Neurons were stimulated with NMDA during 5 min and stained for CaMKIIα mRNA, Smaug1, and synapsin. The number of CaMKIIα mRNA granules at the synapse, associated to S-foci (S+) or not (S−), and the number of synaptic S-foci, associated to CaMKIIα granules or not, are plotted. Approximately 300 synapses from 20 random selected neurons were analyzed in each case. Error bars indicate standard deviation. (B, bottom) Representative immunofluorescent images of synaptic S-foci and CaMKIIα mRNA granules either colocalizing or not colocalizing for each condition. The percentage relative to the total number of synapses and standard error is indicated in each case. (C) Neurons were stimulated with NMDA during 5 min and immunostained for CaMKIIα 30 min after the pulse. Representative dendritic fragments showing an increase of CaMKII signal at the dendritic spine are depicted. Bars: (A, left) 10 µm; (A, right) 1 µm; (B) 1 µm; (C) 2 µm.](JCB_201108159_Fig7){#fig7}

Next, we investigated whether this association is affected by NMDAR stimulation. After a 5-min NMDA pulse, neurons were stained for CaMKIIα mRNA, Smaug1, and synapsin. As before ([Figs. 5 D](#fig5){ref-type="fig"} and [6 B](#fig6){ref-type="fig"}), NMDA exposure provoked the dissolution of the synaptic S-foci, which were reduced from 50 ± 3% to 32 ± 2% ([Fig. 7 B](#fig7){ref-type="fig"}). In addition, we found that the presence of CaMKIIα mRNA granules at the synapse was enhanced by NMDAR stimulation, thus paralleling the recruitment of this messenger upon stimulation of metabotropic receptors ([@bib51]). The proportion of synapses with CaMKIIα mRNA granules increased from 33 ± 3% to 43 ± 3% ([Fig. 7 B](#fig7){ref-type="fig"}). Importantly, in spite of this increase on the number of synapses with CaMKIIα mRNA, the number of synapses where CaMKIIα mRNA colocalized with S-foci was reduced to half the normal values. In resting conditions, 16 ± 2% of the synapses contain CaMKIIα mRNA granules that colocalize with S-foci, and this value dropped to 8 ± 1% upon the NMDA pulse ([Fig. 7 B](#fig7){ref-type="fig"}). Overall, colocalization at the synapse was reduced from 50 ± 3% to 18 ± 3% upon NMDA exposure ([Fig. 7 B](#fig7){ref-type="fig"}). The effect was not restricted to the synapses, and in the dendritic shaft the colocalization between CaMKIIα mRNA granules and S-foci dropped from 45 ± 5% to 30 ± 2%. Whether CaMKIIα mRNA molecules free of Smaug1 represent translating mRNA molecules remains to be investigated. Supporting this possibility, it was recently shown that CaMKIIα mRNA in dendrites is mostly found as a single molecule, and thus, we speculate that either repressed or polysome-engaged CaMKIIα mRNA may render similar discrete stainings. Finally, as expected, we found that CaMKII levels increased locally after NMDA stimulation, as judged by IF analysis with a specific antibody ([Fig. 7 C](#fig7){ref-type="fig"}).

Then, we investigated whether S-foci dissolution by NMDA correlates with a global stimulation of local translation. We used the recently developed fluorescent noncanonical amino acid tagging (FUNCAT) strategy, which was successfully used to demonstrate changes in local translation in dendrites upon exposure to brain-derived neurotrophic factor (BDNF; [@bib28]). In brief, neurons were pulsed with the methionine surrogate azidohomoalanine (AHA) to evaluate basal synthesis, then exposed to NMDA and incubated for variable time periods with a second methionine substitute, homopropargylglycine (HPG; see Materials and methods). Then, incorporated AHA and HPG were covalently tagged with specific fluorescent molecules, and signal intensities were determined by confocal microscopy. First, we assessed whether incorporation of these noncanonical amino acids was blocked by translation inhibitors. We found that cycloheximide completely abrogates the signal in both cell soma and dendrites of both AHA and HPG, which were incorporated linearly during at least 1 h ([Fig. 8, A and B](#fig8){ref-type="fig"}; and not depicted). Then we performed a sequential metabolic labeling to asses the effect of NMDA in local translation at dendrites. We found that a short treatment with NMDA significantly blocked the incorporation of labeled amino acids ([Fig. 8, B and C](#fig8){ref-type="fig"}). The effect was immediate, and three independent experiments showed a reduction of protein synthesis to 42--54% relative to nonstimulated neurons during the first 30 min ([Fig. 8, B and C](#fig8){ref-type="fig"}; and not depicted). Local translation slowly recovered, but it was still significantly lower 60 min after the stimulus. All these observations suggest that local NMDAR activation provokes a global translational silencing, and at the same time allows the translation of CaMKIIα mRNA and other unknown mRNAs by triggering S-foci dissolution.

![**NMDAR activation inhibits global translation at the dendrite.** The FUNCAT strategy was used as indicated in Materials and methods. (A) Cultured neurons were pulsed with HPG or AHA in the presence or absence of cycloheximide (CHX), and the incorporated modified amino acids were covalently coupled to Alexa Fluor 488 or 595. Translation inhibition completely abrogated the signal. Insets show representative dendrite fragments. Bars: (left) 20 µm; (right) 1 µm. (B) HPG and AHA were used sequentially to evaluate the protein synthesis rate before and after the stimulus, respectively. HPG and AHA signal intensities were measured in ∼40 dendrite fragments (total length, 800 µm) for each time point. AHA incorporation at different times after stimulation relative to basal HPG incorporation is plotted. One representative experiment out of four is depicted; error bars indicate the standard deviation from triplicate coverslips. (C) Representative dendrite fragments showing the NMDA inhibitory effect on protein synthesis in dendrite shafts and spines. Bar, 1 µm.](JCB_201108159_Fig8){#fig8}

Smaug1 affects synapse formation
--------------------------------

Translational regulation at the synapse is important for synapse remodeling and stabilization. Having demonstrated that Smaug1 forms mRNA-silencing foci that respond to synaptic stimulation, apparently regulating the key transcript encoding CaMKIIα, among others, we then investigated whether Smaug1 affects synapse formation or function. First, we investigated the expression of this protein during neuron development in vitro by Western blot analysis of Smaug1 and selected synapse components ([Fig. 9 A](#fig9){ref-type="fig"}). We found that Smaug1 expression was negligible during the first week, and that this molecule began to accumulate simultaneously with synapsin and PSD95 after the eighth day in culture ([Fig. 9 A](#fig9){ref-type="fig"}). In contrast, as expected, we found that FMRP and Staufen1 were constitutively expressed (unpublished data). Thus, Smaug1 expression coincides with synaptogenesis in cultured hippocampal neurons.

![**Smaug1 knockdown affects synapse size and number.** (A) Western blot of postnuclear protein extracts (10 or 5 µg) from cultured hippocampal neurons at 1, 8, 15, or 23 d in vitro with the indicated antibodies. (B--F) Neurons were treated with the indicated siRNAs as described in Materials and methods. (B) Smaug1, Map2, and tubulin βIII levels were evaluated by Western blotting. Signal intensity relative to that of β-actin is indicated. An siRNA against Smaug 2 had no effect on Smaug1 levels (not depicted). (C) Representative dendrite fragments stained with the indicated synapse or cytoskeleton markers are shown. (D and E) The size and number of synaptic puncta identified by simultaneous or independent staining of PSD95 and synapsin was measure as indicated in Materials and methods. (D) Summary of the normalized synapse size and number relative to that of siNT-treated neurons in three independent experiments with the siSmaug1 pool, and in a representative experiment comparing the four different siRNA. (E) Synapse size distribution in a representative experiment with the siSmaug1 pool. Random selected dendritic fragments from 10 neurons (total length, 5,000 µm) were analyzed in each case. (F) Neurons were transfected with ECFP and treated with the indicated siRNAs as indicated in Materials and methods. Representative dendrite fragments stained for ECFP and synapsin are shown. Dendritic spines were more numerous upon Smaug1 depletion. Bars, 2 µm.](JCB_201108159_Fig9){#fig9}

To investigate the role of Smaug1 in synaptogenesis, we treated hippocampal cells at the sixth day in culture with a pool of siRNAs against Smaug1 (siSmaug1). RT-PCR analysis performed after 15 d in culture indicated that Smaug1 mRNA levels were reduced to 10% relative to control levels. Efficient depletion of the protein was confirmed by Western blotting and IF analysis ([Figs. 9 B](#fig9){ref-type="fig"} and S1 C). Strikingly, an alteration in synapse puncta was observed in siSmaug1-treated cells. We found that both PSD95 and synapsin clusters were smaller and more numerous than in control or siNT-treated cells ([Fig. 9 C](#fig9){ref-type="fig"} and not depicted). A quantitation of these parameters in five independent experiments indicated that Smaug1 knockdown reduced synapse size to 65% of normal values, and provoked a duplication or triplication of their number ([Fig. 9, D and E](#fig9){ref-type="fig"}). To rule out off-target effects, the four RNAi sequences present in the siSmaug1 pool were analyzed separately. We found that two of them provoked an alteration in synapse number and size comparable to the effect of the pool ([Fig. 9, C and D](#fig9){ref-type="fig"}); all this indicates that the effect is specific to Smaug1 knockdown.

PSD95-containing synapses in hippocampal cells are mostly excitatory, and are located in dendritic spines. To visualize dendritic spines, neurons were transfected with ECFP and stained for PSD95 ([Fig. 9 F](#fig9){ref-type="fig"}). As expected, PSD95 clusters were located at the tip of dendritic spines. Remarkably, dendritic spines were longer and thinner in siSmaug1-treated cells, thus resembling an immature morphology.

Finally, we wondered whether this morphological alteration impaired synapse excitability. To investigate this, we exposed hippocampal neurons to a repeated depolarizing stimuli, which simulates a long-term potentiation (LTP)-like response ([@bib104]), and stained the cells for the early activity-related marker Arc/Arg3.1 ([@bib89]; [@bib88]). As expected, we found that Arc/Arg3.1 was rapidly induced in control or siNT-treated neurons ([Fig. 10, A and B](#fig10){ref-type="fig"}). In these cells, the Arc/Arg3.1 signal intensity doubled at 60 min after stimulation. In striking contrast, Arc/Arg3.1 expression was virtually not induced in siSmaug1-treated neurons ([Fig. 10 B](#fig10){ref-type="fig"}). Altogether these observations indicate that Smaug1 knockdown alters synapse size and number, and concomitantly provokes a defective synaptic response.

![**Smaug1 knockdown affects neuron excitability.** Neurons were treated with the indicated siRNA and exposed to a repeated depolarizing stimulus. (A) Arc/Arg3.1 was detected by IF at the indicated times and shown in glow scale. Bar, 20 µm. (B) Integrated intensity in the cell bodies from 100 neurons from duplicate coverslips was quantified in 20× micrographs. A duplicate experiment with similar results was performed. (C) Hypothetical model for a role of Smaug1 in local translation at the synapse and its regulation by NMDA. CaMKIIα mRNA and other repressed transcripts would be associated with the S-foci, likely as single molecules (see Discussion; [@bib64]). Upon NMDAR stimulation, the S-foci dissolve, likely facilitating the translation of selected mRNA. Simultaneously, local translation is globally repressed. Local translation of CaMKIIα is known to mediate synapse strength, and additional unknown transcripts regulated by Smaug1 may also contribute. (D) Putative SREs are present in the 3′ UTR of CaMKIIα mRNAs from distinct species. In addition, conserved putative SREs are present at the coding region (not depicted).](JCB_201108159_Fig10){#fig10}

Discussion
==========

In this paper, we describe for the first time the existence of a novel kind of mRNA-silencing foci specific to neurons. These silencing foci, which we named S-foci, contain mammalian Smaug1/Samd4A, an RNA-binding protein that belongs to a novel family of posttranscriptional regulators. S-foci are distinct from PBs and SGs, and from other neuronal RNA granules hitherto described (for reviews see [@bib53]; [@bib2]; [@bib20]; [@bib62]; [@bib97]). Like PBs, the S-foci behave as mRNA-silencing foci, as they are able to release transcripts allowing their incorporation to polysomes. Relevantly, S-foci dynamics depend greatly on neuron activity, and our observations suggest that the CaMKII mRNA, and likely other unknown transcripts, cycle between S-foci and polysomes in an activity-dependent manner, thus paralleling the cycling of specific mRNAs between PBs and polysomes in other cellular contexts. We speculate that similar foci exist in *Drosophila* peripheral neurons, where dSmaug regulates specific mRNAs ([@bib19]). Supporting this assumption, *Drosophila* Smaug is found in foci in fly embryos and forms granules when expressed in cell lines ([@bib9]; [@bib106]; [@bib76]).

The molecular mechanism for mRNA repression by mammalian Smaug1 is unknown. *Drosophila* Smaug acts by two pathways: it represses translation by blocking initiation at the level of 4E--4G interaction and by capturing target transcripts in repressed RNP complexes ([@bib48]). In addition, *Drosophila* Smaug initiates mRNA decay by triggering deadenylation ([@bib67]; [@bib106]; [@bib94]; [@bib75]; [@bib76]). Paralleling the functions of the *Drosophila* molecule, mammalian Smaug1 may block initiation, may mediate deadenylation, which is frequent in neuronal mRNAs ([@bib30]), or may govern the formation of masking RNPs where mRNAs are sequestered from translation factors. All these mechanisms are compatible with the formation of Smaug1 mRNA-silencing foci*.* Whether Smaug1 aggregation in discrete structures is required for efficient mRNA repression is unknown. Several proteins involved in mRNA silencing have distinct oligomerization domains ([@bib40]; [@bib77]; [@bib97]), and how aggregation contributes to mRNA repression is a matter of debate. Nevertheless, our finding that S-foci formation does not require binding to RNA indicates that aggregation is not a consequence of mRNA silencing, and supports the hypothesis that the formation of oligomeric structures is important for Smaug1 function. Transcripts located at the synapses are transported relatively long distances from the cell body, and this transport is performed in granules ([@bib54]; [@bib55]; [@bib88]; [@bib50]; [@bib34]; [@bib62]). Thus, besides putatively enhancing translational repression by physical sequestration of mRNAs, the self-aggregation of a translational regulator may contribute to the assembly of transport-competent complexes carrying repressed mRNAs. Conversely, dissolution of S-foci upon synaptic stimulation may contribute to restrict the movement of transcripts that are required at the synapse. The molecular mechanism underlying S-foci aggregation is unknown, and is likely to involve oligomerization domains and motor molecules, which govern the assembly of mRNA-silencing foci in general ([@bib40]; [@bib60]; [@bib77]).

We found that mammalian S-foci associate to synapses and selectively respond to NMDAR activation, dissolving and facilitating the translational activation of CaMKIIα mRNA and a plethora of unknown transcripts. The response is immediate and transient, and involves calcium influx and PI3K signaling (see the hypothetical model in [Fig. 10 C](#fig10){ref-type="fig"}). Whether Smaug1 oligomerization is directly controlled by this signaling pathway remains to be investigated. We found that AMPAR or GABAR activity do not affect S-foci dynamics. In contrast, FMRP granules respond to AMPAR stimulation (this paper and [@bib3]), which indicates that distinct neuronal granules specifically respond to distinct stimuli. Further supporting a remarkable specificity of the response, we found that while Smaug1-mediated repression is released, NMDAR stimulation globally inhibits local protein synthesis, in agreement with previous studies ([@bib57]; [@bib61]; [@bib79]; [@bib91], [@bib92], [@bib93]; [@bib81]).

The messenger encoding CaMKIIα is activated by NMDAR stimulation via several mechanisms, including cytoplasmic polyadenylation and relief from microRNA silencing ([@bib79]; [@bib88]; [@bib47]; [@bib4]; [@bib18]), all compatible with the Smaug1-mediated repression suggested here. Human Smaug1 recognizes the SRE motifs from the *Drosophila* nanos mRNA ([@bib9]), and thus we speculate that the transcripts regulated by mammalian Smaug1 will contain related motifs. A putative SRE is present in the 3′ untranslated region (UTR) of the human, rat, and mouse CaMKIIα ([Fig. 10 D](#fig10){ref-type="fig"}). The relevance of these elements in the regulation of CaMKIIα mRNA by Smaug1 remains to be investigated. It is well established that CaMKIIα affects spine size and synaptic function ([@bib72]), and thus, we speculate that dysregulation of this messenger contributes to the serious synaptic defect provoked by Smaug1 depletion.

Smaug1 is expressed late during neuronal differentiation, coincident with the expression of key synaptic components and with the appearance of visible synaptic contacts. Several mRNAs relevant to synapse function start to accumulate at this developmental time ([@bib70]), and thus Smaug1 may have a role in the local control of these new mRNAs. In addition to its contribution to the regulation of local translation by synaptic stimulation, we speculate that Smaug1 helps the profound remodeling of the transcriptome that occurs during synaptogenesis ([@bib70]). We speculate that, paralleling the role of *Drosophila* Smaug during the maternal-to-zygotic transition, during which fly Smaug down-regulates hundreds of maternal mRNAs ([@bib94]; [@bib15]), mammalian Smaug1 may be involved in a massive silencing of early mRNAs that are not required after synaptogenesis. These putative Smaug1 mRNA targets remain to be identified. SREs may have loops up to seven nucleotides long, and the secondary structure that surrounds the motifs may affect their accessibility ([@bib7], [@bib8]; [@bib44]; [@bib49]; [@bib68]; [@bib38]; [@bib58]; [@bib74]). Thus, the identification of mammalian Smaug1 targets will require intense investigation.

Materials and methods
=====================

Neuron culture, cell lines, and transfection
--------------------------------------------

U2OS and HeLa cells were from the American Tissue Culture Collection and grown and maintained as indicated. Hippocampal cultures were prepared as described previously ([@bib13]). In brief, hippocampi were dissected from Sprague Dawley rats at embryonic day 18 and digested with trypsin. Cells were seeded on poly-[d]{.smallcaps}-lysine (Sigma-Aldrich)-coated glass coverslips. Cultures were maintained in Neurobasal medium (NB; Invitrogen) supplemented with B27 (Invitrogen) and glutamine (complete NB; Invitrogen) at 5% CO~2~. Cell lines were transfected with either Lipofectamine 2000 Transfection Reagent (Invitrogen) or Jet Prime (Polyplus Transfection) according to manufacturer's instructions. Neurons were transfected one day after plating using Lipofectamine 2000 Transfection Reagent (Invitrogen) during 4 h, and analyzed at day 15. The following constructs were used: (a) A full-length Smaug1 fused to either EGFP or V5 ([@bib9]). (b) ECFP-ΔSAM, including two fragments of hSmaug1: amino acids 1--317 fused to amino acids 376--717 and tagged with ECFP in the N terminus. An hSmaug1 fragment spanning amino acids 1--376 was PCR-amplified from the pCDNA6--V5--hSmaug1 described previously ([@bib9]) using 5′-TAATACGACTCACTATAGGG-3′ and 5′-AAGGCGAGCCTCGAGGGTG-3′ as primers, digested with HindIII and XhoI, and inserted between the HindIII and SalI sites of pECFP-C3 (Takara Bio Inc.). A second amplification was performed with 5′-GCGAGCCTCGGGTGTGTTACGAGC-3′ and 5′-CATGGTCCTGCTGGAGTTCGTG-3′ as primers. The hSmaug1 N-terminus hSmaug1 including amino acids 376--717 was amplified using 5′-GCTCGTAACACACCCGAGGCTCGC-3′ and 5′-CGTCGCCGTCCAGCTCGACCAG-3′ as primers. The last two PCR products contained a 12-bp overlapping region, and were fused by splicing with overlapping extension PCR (SOE-PCR), using the primers 5′-CGTCGCCGTCCAGCTCGACCAG-3′ and 5′-CATGGTCCTGCTGGAGTTCGTG-3′. This PCR product was digested with HindIII and BamHI and inserted between the HindIII and BamHI site of the pECFP-N1 plasmid (Takara Bio Inc.). (c) ECFP-SAM: The region encoding the RBD was PCR-amplified from a hSmaug1-ECFP construction ([@bib9]) using the primers 5′-CCGCTGCTCGGAATTCATTCCA-3′ and 5′-AAGGCGAGCCTCGAGGGTG-3′, digested with EcoRI and XhoI, and inserted between the EcoRI and SalI sites of the pECFP-C1 plasmid (Takara Bio Inc.).

siRNA treatment
---------------

U2OS cells were treated with a nontargeting siRNA (siNT) 5′-UAGCGACUAAACACAUCAA-3′; an siRNA anti-Hedls (siHedls, catalog no. 004397; Thermo Fisher Scientific); anti-Rck/p54 (siRck/p54, catalog no. 0143295); or an siRNA against 4ET (5′-GAACAAGAUUAUCGACCUA-3′; [@bib36]) used at 50 nM, and transfected 72 h afterward with the indicated plasmids. Jet Prime was used for both steps. Hippocampal neurons were allowed to grow for 6 d in vitro, incubated with 100 nM siRNA (Thermo Fisher Scientific) complexed with Lipofectamine 2000 Transfection Reagent (Invitrogen) for 4 h, and analyzed at 15 d in vitro unless otherwise indicated. Either a pool against rat Smaug1 (catalog no. M-086491-00-0010) containing the sequences 5′-AAUAUAAGCUCCUAUCUAC-3′ (siSmaug1*a*), 5′-GACCGGACCUCCACAAUCU-3′ (siSmaug1*b*), 5′-UGGCAGAACUCUCGGGAUU-3′ (siSmaug1*c*), and 5′-ACGCGAAAGUAGAGUAUAU-3′ (siSmaug1*d*) at 25 nM each or the individual sequences at 100 nM were used. A pool of four sequences against rat Smaug2 (siSmaug2, catalog no. M-081919-00) and an siCONTROL nontargeting pool (D-001810-10; Thermo Fisher Scientific) were used at 100 nM.

Drug treatment and neuron stimulation
-------------------------------------

In all cases, stock solutions were diluted into conditioned medium. Sodium arsenite, used at 1 mM cycloheximide, and puromycin, used at 250 µg/ml, were obtained from Sigma-Aldrich. Emetine, used at 1 µg/ml, was a gift from I.D. Algranatti (Fundación Instituto Leloir, Buenos Aires, Argentina). Hippuristanol was provided by J. Pelletier (McGill University, Montreal, Quebec, Canada) and used at 0.01 mg/ml. Neuron depolarization was induced in 17--20-d cultures by increasing KCl (Sigma-Aldrich) concentration up to 55 mM during 10 min unless otherwise indicated. When indicated, depolarization was performed in the presence of kynurenic acid, used at 4 mM, picrotoxin, AP5, or CNQX (provided by A. Schinder, Fundación Instituto Leloir; and O. Uchitel, University of Buenos Aires, Buenos Aires, Argentina), all used at 50 µM and added 5 min before stimulation. For NMDAR stimulation, 1 µM TTX (Tocris Bioscience) was applied overnight, followed by a five min-pulse with 30 µM NMDA (Sigma-Aldrich) and a variable recovery period in NB. Wortmannin and EGTA-AM (Sigma-Aldrich), used at 20 µM, were added five min before neuron stimulation. KN93, used at 2 µM, and LY294002, used 10 µM, were from Sigma-Aldrich. Stimulation by repeated depolarization was induced as described previously ([@bib104]). In brief, primary hippocampal neurons at 24 d in vitro were treated with 1 µM TTX for 1 d to block spontaneous activity. Then, repeated depolarization stimuli with 90 mM KCl in isotonic Tyrode's solution during 3 min were applied four times with 10 min intervals. TTX was applied during the resting intervals and after the stimulation phase.

FUNCAT
------

For labeling of newly synthesized proteins, HPG and AHA, both from Invitrogen, were used according to the manufacturer's instructions. Before labeling, neurons were incubated during 30 min in methionine-free DME (Sigma-Aldrich) plus TTX, after an overnight treatment with TTX in NB. Then, HPG was added during 15 min. After a 5-min pulse with NMDA, without any tagged amino acid, and in the absence of methionine and TTX, cells were incubated with AHA during the indicated times. After fixation and permeabilization, cells were incubated with Alexa Fluor 594 azide (Alexa Fluor 594 carboxamido-(6-azidohexanyl) bis(triethylammonium salt); Invitrogen), which reacts with the azide group of AHA-bearing proteins, and then with Alexa Fluor 488 alkyne (Alexa Fluor 488 5-carboxamido-(propargyl), bis(triethylammonium salt)), which reacts with the HPG azide group. Signal intensities were measured in dendrite fragments located at 50 µm or longer distances from the soma to minimize contribution from proteins delivered from the cell body ([@bib28]).

IF, FISH, and image analysis
----------------------------

IF of cultured cells was performed after fixation, permeabilization, and blocking as usual ([@bib95], [@bib96]; [@bib60]). Primary antibodies were diluted as follows: anti-mammalian Smaug1, 1:300--1:1,000 ([@bib9]); rabbit polyclonal anti-Dcp1 (a gift from J.L. Andersen, University of California, San Diego, La Jolla, CA), 1:100; monoclonal IgG2a anti Dcp1a (Abnova Corporation), 1:1,000; polyclonal rabbit anti-Hedls and anti Rck/p54 (Bethyl Laboratories, Inc.), 1:500; monoclonal IgG2a anti-PSD95 (Millipore), 1:100; IgG2b anti-tubulin βIII and IgG1 anti-MAP2 (both from Sigma-Aldrich), 1:500; IgG1 anti-Synapsin (Synaptic Systems), 1:100; polyclonal anti-Arc (catalog no. 156 003; Synaptic Systems), 1:500; polyclonal anti-Staufen ([@bib95]), 1:400; IgG2b anti-FMRP, clone 7G1-1 (Developmental Studies Hybridoma Bank), 1:50; IgG1 anti-TIAR (BD), 1:100; and monoclonal anti-CaMKII (Abcam), 1:500. Secondary antibodies coupled to Alexa Fluor 488, Alexa Fluor 555, or Alexa Fluor 666, used at 1:500--1:1,000, were obtained from Invitrogen. Secondary antibodies coupled to Cy2, Cy3, or Cy5, used at 1:300--1:500, were from Jackson ImmunoResearch Laboratories, Inc. Phalloidin conjugated to FITC (Sigma-Aldrich) or to Alexa Fluor 546 (Invitrogen) was used.

Brain sections, provided by A. Schinder and A.J. Ramos (University of Buenos Aires) were stained in a free-floating system, as described previously ([@bib6]). In brief, after antigen retrieval by treatment at 95°C for 5 min, vibratome sections were blocked in 10% normal donkey serum in PBS containing 0.3% Triton X-100, and incubated overnight with anti-Smaug (1:100), anti-synapsin (1:200), or anti-tubulin βIII (1:200) at 4°C. Donkey secondary antibodies anti--rabbit, anti--mouse IgG1, or IgG2b (Jackson) were used at 1:250. Sections were mounted in PVA-Dabco (Sigma-Aldrich).

For FISH, a pBlueScript plasmid (Agilent Technologies) containing 240 bp from the coding region and contiguous 3,280 bp from the 3′ UTR of rat CaMKIIα was provided by S. Kindler (University Medical Center Hamburg-Eppendorf, Hamburg, Germany). Sense and antisense digoxigenin-RNA probes were synthesized according to the manufacturer's instructions (Roche), and combined FISH-IF was performed as described previously ([@bib95]). In brief, cells were fixed in 4% paraformaldehyde, 4% sucrose, and 2 mM MgCl~2~ in PBS for 15 min at 37°C; washed three times in 4% sucrose and PBS; and UV cross-linked (CL program, GS Gene Linker; Bio-Rad Laboratories, Inc.). Cells were then treated with 0.3% Triton X-100 in PBS for 5 min, washed with 2 mM MgCl~2~ in PBS, and dried completely. After prehybridization in 50% formamide, 5× SSC, 0.2% SDS, 50 mg/ml heparin, 250 mg/ml salmon sperm DNA, and 250 mg/ml yeast tRNA (all from Sigma-Aldrich), overnight hybridization was performed at 55°C in the same solution supplemented with 100 mg/ml heparin and 100 ng/ml digoxigenin-riboprobe. After washing twice at room temperature with 1× SSC, 0.1% SDS, and twice at 50°C with 0.2× SSC, 0.1% SDS, blocking was performed with 1% blocking reagent (Boehringer Ingelheim) in PBS. The probe signal was amplified in one or two steps with the following antibodies: biotinylated mouse antidigoxin (Sigma-Aldrich) or sheep antidigoxigenin (Boehringer Ingelheim) followed by biotinylated donkey anti--sheep (Jackson ImmunoResearch Laboratories, Inc.). Then, anti--mouse A488 or streptavidin coupled to Cy2 (Jackson ImmunoResearch Laboratories, Inc.) was used. All incubations were performed for 2 h at room temperature and were followed by three washes in PBS with Tween 20 (PBST). The first antibody for the IF was either included in the antidigoxin antibody solution, or used after the biotinylated donkey anti--sheep. The secondary antibody for IF was always included in the streptavidin mix.

Images were acquired with PASCAL-LSM and LSM510 Meta confocal microscopes (Carl Zeiss), using C-Apochromat 40×/1.2 W Corr or 63×/1.2 W Corr water immersion objectives for the LSM, and an EC "Plan-Neofluor" 40×/1.30 NA oil or Plan-Apochromat 63×/1.4 NA oil objective lenses for the LSM510 Meta. Images were acquired with LSM software (Carl Zeiss), and pixel intensity was always lower that 250, with 255 being the level of saturation. Equipment adjustment was assessed by using 1 µm FocalCheck fluorescent microspheres (Invitrogen). No filters or gamma adjustment were used previous to the analysis of the object's size, number, or intensity with the ImageJ software. The size and number of synapse puncta or Smaug granules was analyzed in maximum-intensity z-stacks of 0.45-µm slices (63×). Values in [Fig. 4 A](#fig4){ref-type="fig"}; [Fig. 5 (A, B, D, E and F)](#fig5){ref-type="fig"}, and Fig. [6 (A--C)](#fig6){ref-type="fig"} are normalized to the number of synapses with S-foci under resting conditions, which were 62% for [Fig. 4 A](#fig4){ref-type="fig"}, 75% for [Fig. 5 (A, B, and E)](#fig5){ref-type="fig"} and [Fig. 6 (A--C)](#fig6){ref-type="fig"}, and 67% for [Fig. 5 D](#fig5){ref-type="fig"}.

Magnifications in [Fig. 1 (A and B)](#fig1){ref-type="fig"}, [Fig. 2 (A and B)](#fig2){ref-type="fig"}, [Fig. 3 (A, B, and D)](#fig3){ref-type="fig"}, [Fig. 7 (A and B)](#fig7){ref-type="fig"}, [Fig. 8 C](#fig8){ref-type="fig"}, [Fig. 9 (C and E)](#fig9){ref-type="fig"}, and [Fig. 10 A](#fig10){ref-type="fig"} were scaled using bilinear interpolation; and a Gaussian Blur, Sigma radius Max 2 filter, was applied to [Fig. 4 A](#fig4){ref-type="fig"}.

Hippocampus fractionation
-------------------------

Hand-dissected hippocampuses from adult mice were fractionated as described previously ([@bib71]). In brief, a crude synaptosome preparation was extracted in 2% Triton X-100, pH 6, followed by 1% Triton X-100, pH 8.0, to obtain a fraction enriched in soluble presynaptic components, and a fraction containing postsynaptic densities and insoluble presynaptic proteins.

Western blotting and RT-PCR
---------------------------

Western blotting was performed by standard procedures using polyvinylidene fluoride membranes (Immobilon-P polyvinylidene difluoride; Millipore), LumiGlo (Cell Signaling Technology), and Hyperfilm (GE Healthcare). Primary antibodies were used as follows: anti-Smaug1 ([@bib9]), diluted 1:5,000--1:10,000; anti--β-actin, 1:5,000--1:10,0000 (Sigma-Aldrich); anti-PSD95 (Millipore), 1:1,000; anti--βIII-tubulin and anti-MAP2 (both from Sigma-Aldrich), 1:5,000; anti-Synapsin (Synaptic Systems), 1:5,000; and anti-Hedls. For semiquantitative analysis, autoradiographs were scanned and signal intensity was assessed with the ImageJ software. RT-PCR was performed as described previously ([@bib9]) using the following primers for Smaug1: 5′-TCGACAGCAAAGAAATCGTG-3′ and 5′-AAGGCTGCAAAGTGTCTTGG-3′; and the following primers for β-actin: 5′-TCTGTGTGGATTGGTGGCTCTA-3′ and 5′-CTGCTTGCTGATCCACATCTG-3′.

Statistics
----------

The number of synapses, number cells, and/or dendritic lengths analyzed are indicated in each figure panel. Each experimental point includes duplicate or triplicate coverslips. P-values (\*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001) relative to control treatments according to two-way ANOVA or the indicated test were determined using Infostat (Universidad Nacional de Córdoba) or Instat software (GraphPad Software, Inc.). Error bars represent standard error from independent experiments unless otherwise indicated.

Online supplemental material
----------------------------

Fig. S1 shows that a proportion of neuronal S-foci are in contact with PBs under resting conditions and that S-foci localize adjacent to SGs induced in neurons upon exposure to oxidants. Fig. S2 shows that transfected Smaug1-ECFP or ΔSAM-ECFP form foci in cell lines, which are distinct from SGs and in close contact with PBs. Online supplemental material is available at <http://www.jcb.org/cgi/content/full/jcb.201108159/DC1>.

This paper is dedicated to the memory of Dr. David R. Colman. Dr. Colman died on 1 June 2011.
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